El-Khayat H, et al. - In adolescent genotype-4 hepatitis C patients, researchers conducted this investigation to assess 8 vs 12-week treatment effectiveness and safety with sofosbuvir (SOF)/ledipasvir (LVD). The study sample consisted of 157 chronic hepatitis C-infected adolescent patients (mean age 14±2 years, 62% males). Participants in the study received a morning dose of SOF (400 mg)/LVD (90 mg) as a single tablet for 8 and 12 weeks. At weeks 4 and 8, end of treatment (8/12) and 12 weeks after the end of treatment (SVR12), laboratory and biochemical monitoring were performed. Investigators found that 8 weeks of SOF/LVD combination treatment in adolescent genotype-4 patients is as effective and safe as 12 weeks of treatment. Fatigue, headache, nausea and epigastric tenderness were the main adverse effects for the 8-week patient group. Adverse events were epigastric tenderness, nausea, diarrhea and rash for the 12-week-treated group.